Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir: a prospective controlled study

Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-11001495

Enrollment

Unknown

Registered

2011-09-02

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

Telbivudine plus adefovir:Telbivudine 600 mg/day , Adefovir 10 mg/day

Lamivudine plus adefovir:Lamivudine 100 mg/day , Adefovir 10 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Srum HBV DNA levels >3 log10 copies/ml, regardless of hepatitis B e antigen (HBeAg) status and serum ALT levels

Exclusion criteria

Exclusion criteria: Previously received or being treated with any other anti-HBV drugs in addition to adefovir; evidence of ADV associated resistance (rtA181V or rtN236T); presence of serum antibodies against hepatitis A virus(HAV); hepatitis C virus (HCV), hepatitis E virus (HEV)or human immunodeficiency virus (HIV); breast-feeding, pregnancy or inadequate contraceptive measures; other acquired or inherited causes of liver disease; coexisting serious medical disease; advanced liver diseases (including decompensated cirrhosis, severe hepatitis, and hepatic carcinoma).

Design outcomes

Primary

Measure	Time frame
HBV DNA;ALT;HBeAg;	—

Secondary

Measure	Time frame
Resistance;	—

Countries

China

Contacts

Public ContactHong Tang

htang6198@hotmail.com+86 28 85242650

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026